Identification of Novel and Known LDLR Variants Triggering Severe Familial Hypercholesterolemia in Saudi Families.

Familial hypercholesterolemia cholesterol coronary artery disease low-density lipoprotein receptor next-generation sequencing variant

Journal

Current vascular pharmacology
ISSN: 1875-6212
Titre abrégé: Curr Vasc Pharmacol
Pays: United Arab Emirates
ID NLM: 101157208

Informations de publication

Date de publication:
2022
Historique:
received: 27 07 2021
revised: 20 01 2022
accepted: 20 01 2022
pubmed: 8 3 2022
medline: 5 11 2022
entrez: 7 3 2022
Statut: ppublish

Résumé

Familial hypercholesterolemia (FH) is a common illness mainly caused by variants occurring in the low-density lipoprotein receptor (LDLR) gene. FH is a leading cause of coronary artery disease. This study aims to determine genetic defect(s) in homozygous and heterozygous FH index patients and their first-degree blood relatives and understand the genotype-phenotype correlation. This study employed the genetic screening of FH-related genes by next-generation sequencing and cascade screening by capillary sequencing. We identified the presence of a novel frameshift variant [c.335_336insCGAG, p.(F114Rfs*17)] and three known missense variants [c.622G>A, p.(E208K)], [c.1474G>A, p.(D492N)], [c.1429G>A, p.(D477N)] in the LDLR gene of four unrelated Saudi families with FH. In proband 1, a nonsense variant c.1421C>G, p.(S474*) was also detected at exon 9 of the lipoprotein lipase gene. The segregation arrangement of the identified variants corresponded with the clinical characteristics. In this study, all the detected variants were confined in the ligand-binding domain and epidermal growth factor (EGF)-precursor homology domain of the LDLR protein, which portrayed severe clinical phenotypes of FH. Moreover, these LDLR variants were in a highly conserved residue of the proteins. In addition to the finding of the novel variant in the LDLR gene that extends the spectrum of variants causing FH, the results of this study also support the need for diagnostic screening and cascade genetic testing of this high-risk condition and to understand the genotype-phenotype correlation, which could lead to better prevention of coronary artery disease.

Sections du résumé

BACKGROUND
Familial hypercholesterolemia (FH) is a common illness mainly caused by variants occurring in the low-density lipoprotein receptor (LDLR) gene. FH is a leading cause of coronary artery disease.
OBJECTIVE
This study aims to determine genetic defect(s) in homozygous and heterozygous FH index patients and their first-degree blood relatives and understand the genotype-phenotype correlation.
METHODS
This study employed the genetic screening of FH-related genes by next-generation sequencing and cascade screening by capillary sequencing.
RESULTS
We identified the presence of a novel frameshift variant [c.335_336insCGAG, p.(F114Rfs*17)] and three known missense variants [c.622G>A, p.(E208K)], [c.1474G>A, p.(D492N)], [c.1429G>A, p.(D477N)] in the LDLR gene of four unrelated Saudi families with FH. In proband 1, a nonsense variant c.1421C>G, p.(S474*) was also detected at exon 9 of the lipoprotein lipase gene. The segregation arrangement of the identified variants corresponded with the clinical characteristics. In this study, all the detected variants were confined in the ligand-binding domain and epidermal growth factor (EGF)-precursor homology domain of the LDLR protein, which portrayed severe clinical phenotypes of FH. Moreover, these LDLR variants were in a highly conserved residue of the proteins.
CONCLUSION
In addition to the finding of the novel variant in the LDLR gene that extends the spectrum of variants causing FH, the results of this study also support the need for diagnostic screening and cascade genetic testing of this high-risk condition and to understand the genotype-phenotype correlation, which could lead to better prevention of coronary artery disease.

Identifiants

pubmed: 35249492
pii: CVP-EPUB-121319
doi: 10.2174/1570161120666220304101606
doi:

Substances chimiques

Receptors, LDL 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

361-369

Informations de copyright

Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Auteurs

Fahad Alnouri (F)

Cardiovascular Prevention Unit, Department of Adult Cardiology, Prince Sultan Cardiac Centre, Riyadh, Saudi Arabia.

Faisal A Al-Allaf (FA)

Department of Medical Genetics, Faculty of Medicine, Umm Al-Qura University, Makkah Al Mukarramah, Saudi Arabia.
Science and Technology Unit, Umm Al-Qura University, Makkah Al Mukarramah, Saudi Arabia.
Molecular Diagnostics Unit, Department of Laboratory and Blood Bank, King Abdullah Medical City, Makkah Al Mukarramah, Saudi Arabia.

Mohammad Athar (M)

Department of Medical Genetics, Faculty of Medicine, Umm Al-Qura University, Makkah Al Mukarramah, Saudi Arabia.
Science and Technology Unit, Umm Al-Qura University, Makkah Al Mukarramah, Saudi Arabia.

Khalid Al-Rasadi (K)

Director of Medical Research Center, Sultan Qaboos University, Muscat, Oman.

Dalal Alammari (D)

Department of Dermatology, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.

Menwar Alanazi (M)

Cardiovascular Prevention Unit, Department of Adult Cardiology, Prince Sultan Cardiac Centre, Riyadh, Saudi Arabia.

Zainularifeen Abduljaleel (Z)

Department of Medical Genetics, Faculty of Medicine, Umm Al-Qura University, Makkah Al Mukarramah, Saudi Arabia.
Science and Technology Unit, Umm Al-Qura University, Makkah Al Mukarramah, Saudi Arabia.

Zuhier Awan (Z)

Department of Clinical Biochemistry, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.

Abdellatif Bouazzaoui (A)

Department of Medical Genetics, Faculty of Medicine, Umm Al-Qura University, Makkah Al Mukarramah, Saudi Arabia.
Science and Technology Unit, Umm Al-Qura University, Makkah Al Mukarramah, Saudi Arabia.

Ghida Dairi (G)

Department of Medical Genetics, Faculty of Medicine, Umm Al-Qura University, Makkah Al Mukarramah, Saudi Arabia.

Wafa M Elbjeirami (WM)

Molecular Diagnostics Unit, Department of Laboratory and Blood Bank, King Abdullah Medical City, Makkah Al Mukarramah, Saudi Arabia.

Hussam Karra (H)

Cardiovascular Prevention Unit, Department of Adult Cardiology, Prince Sultan Cardiac Centre, Riyadh, Saudi Arabia.

Abdulhalim J Kinsara (AJ)

Ministry of National Guard-Health Affairs, King Abdullah International Medical Research Center, King Saud Bin Abdulaziz University for Health Sciences, COM-WR, Riyadh, Saudi Arabia.

Mohiuddin M Taher (MM)

Department of Medical Genetics, Faculty of Medicine, Umm Al-Qura University, Makkah Al Mukarramah, Saudi Arabia.
Science and Technology Unit, Umm Al-Qura University, Makkah Al Mukarramah, Saudi Arabia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH